Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 32

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Discontinuation of Growth Hormone (GH) Treatment during the Transition Phase Is an Important Factor Determining the Phenotype of Young Adults with Nonidiopathic Childhood-Onset GH Deficiency

Kołtowska-Häggström, Maria, Geffner, Mitchell E., Jönsson, Peter, Monson, John P., Abs, Roger, Hána, Václav, Höybye, Charlotte, Wollmann, Hartmut A.·2010·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2009-2013
Open this paper in CoChat — free account

Abstract

Context: Little is known about the impact of childhood-onset GH deficiency (GHD), in particular the duration of GH cessation during the transition phase, on adult phenotype. Objective: We investigated the association between the manifestations and management of GHD during childhood/adolescence and the clinical features of GHD in adulthood. Design/Setting/Patients/Intervention: Patients with reconfirmed childhood-onset GHD who resumed GH treatment as adults were identified from two sequential databases (n = 313). The cohort was followed up longitudinally from GH start in childhood to reinitiation of treatment in adulthood and 1 yr beyond. Analyses were performed in the total cohort and in subgroups of patients with idiopathic GHD (IGHD) and non-IGHD. The cohorts were stratified based on duration of GH cessation (short, ≤2 yr; long, >2 yr). Main Outcome Measures: Regimen of pediatric GH administration, duration of GH interruption, IGF-I sd score, lipid concentrations, and quality of life were measured. Results: Mean duration of GH interruption was 4.4 yr. IGF-I sd score in adulthood was related to severity of childhood GHD. In non-IGHD patients, a longer duration of GH interruption was associated with a worse lipid profile (P < 0.0001). Non-IGHD patients who gained more height during childhood GH treatment reported better quality of life than those who gained less height (P < 0.05). Conclusions: Pediatricians should tailor GH treatment, not only for its beneficial effect on growth but also for future health in adulthood. In adults with reconfirmed GHD, particularly those with non-IGHD, early recommencement of GH should be considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2009-2013

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 32

  1. Shalet, 2004, Stepping into adulthood: the transition period, Horm Res, 62, 15, 10.1159/000080904 · DOI
  2. Geffner, 2003, Transition to the adult endocrine clinic: testing pituitary function—what tests and when, Growth Horm IGF Res, 13, S117, 10.1016/S1096-6374(03)00067-4 · DOI
  3. Mauras, 2005, Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial, J Clin Endocrinol Metab, 90, 3946, 10.1210/jc.2005-0208 · DOI
  4. Höybye, 2007, Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency, Eur J Endocrinol, 157, 589, 10.1530/EJE-07-0364 · DOI
  5. Attanasio, 1997, Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group, J Clin Endocrinol Metab, 82, 82
  6. Riis, 2003, Thirty years of bioethics: the Helsinki Declaration 1964–2003, New Rev Bioeth, 1, 15, 10.1080/1740028032000131396 · DOI
  7. Geffner, 2004, Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database), J Clin Endocrinol Metab, 89, 5435, 10.1210/jc.2004-0667 · DOI
  8. Gutiérrez, 2008, Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database), Pharmacoepidemiol Drug Saf, 17, 90, 10.1002/pds.1510 · DOI
  9. 2004, Aetiology of growth hormone deficiency (KIMS classification list), In: Abs R, Feldt-Rasmussen U, eds. Growth hormone deficiency in adults: 10 years of KIMS. Oxford, UK: Oxford PharmaGenesis Ltd.;, 346
  10. Tanner, 1966, Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I, Arch Dis Child, 41, 454, 10.1136/adc.41.219.454 · DOI · Paper page
  11. Brabant, 2003, Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study, Horm Res, 60, 53
  12. Lie, 1976, Cholesterol oxidase-based determination, by continuous-flow analysis, of total and free cholesterol in serum, Clin Chem, 22, 1627, 10.1093/clinchem/22.10.1627 · DOI · Paper page
  13. Lopes-Virella, 1977, Cholesterol determination in high-density lipoproteins separated by three different methods, Clin Chem, 23, 882, 10.1093/clinchem/23.5.882 · DOI · Paper page
  14. Fossati, 1982, Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide, Clin Chem, 28, 2077, 10.1093/clinchem/28.10.2077 · DOI · Paper page
  15. Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page
  16. McKenna, 1999, The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency, Qual Life Res, 8, 373, 10.1023/A:1008987922774 · DOI · Paper page
  17. Brabant, 2007, Clinical implications of residual growth hormone (GH) response to provocative testing in adults with severe GH deficiency, J Clin Endocrinol Metab, 92, 2604, 10.1210/jc.2007-0153 · DOI
  18. Fisker, 1999, Impact of gender and androgen status on IGF-I levels in normal and GH-deficient adults, Eur J Endocrinol, 141, 601, 10.1530/eje.0.1410601 · DOI
  19. Colao, 2002, The cardiovascular risk of GH-deficient adolescents, J Clin Endocrinol Metab, 87, 3650, 10.1210/jcem.87.8.8777 · DOI
  20. Attanasio, 2004, Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients, J Clin Endocrinol Metab, 89, 4857, 10.1210/jc.2004-0551 · DOI
  21. Carroll, 2004, Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth, J Clin Endocrinol Metab, 89, 3890, 10.1210/jc.2003-031588 · DOI
  22. JAMA, 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  23. Davis, 1980, Correlations of plasma high-density lipoprotein cholesterol levels with other plasma lipid and lipoprotein concentrations, Circulation, 62, IV24
  24. Götherström, 2007, A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults, J Clin Endocrinol Metab, 92, 1442, 10.1210/jc.2006-1487 · DOI
  25. Florakis, 2000, Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study, Clin Endocrinol (Oxf), 53, 453, 10.1046/j.1365-2265.2000.01108.x · DOI
  26. Abs, 2006, Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults—a KIMS database analysis, Eur J Endocrinol, 155, 79, 10.1530/eje.1.02179 · DOI
  27. McMillan, 2003, Psychological effects of withdrawal of growth hormone therapy from adults with growth hormone deficiency, Clin Endocrinol (Oxf), 59, 467, 10.1046/j.1365-2265.2003.01870.x · DOI
  28. Stouthart, 2003, Quality of life of growth hormone (GH) deficient young adults during discontinuation and restart of GH therapy, Psychoneuroendocrinology, 28, 612, 10.1016/S0306-4530(02)00045-8 · DOI
  29. Sartorio, 1995, Growth hormone treatment in adults with childhood onset growth hormone deficiency: effects on psychological capabilities, Horm Res, 44, 6, 10.1159/000184582 · DOI
  30. Christensen, 2007, An evaluation of the relationship between adult height and health-related quality of life in the general UK population, Clin Endocrinol (Oxf), 67, 407, 10.1111/j.1365-2265.2007.02901.x · DOI
  31. Dixon, 2001, Quality of life after lap-band placement: influence of time, weight loss, and comorbidities, Obes Res, 9, 713, 10.1038/oby.2001.96 · DOI · Paper page
  32. Abrams, 2008, GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables, Eur J Endocrinol, 159, 825, 10.1530/EJE-08-0448 · DOI

Cited by

See all 32

Metadata

Authors
Kołtowska-Häggström, M., Geffner, M. E., Jönsson, P., Monson, J. P., Abs, R., Hána, V., Höybye, C., & Wollmann, H. A.
Affiliations
  • KIGS/KIMS Medical Outcomes (M.K.-H., P.J.), Pfizer Endocrine Care, SE-190 91 Sollentuna, Sweden
  • The Saban Research Institute (M.E.G.), Childrens Hospital Los Angeles, Los Angeles, California 90027
  • Centre for Clinical Endocrinology (J.P.M.), William Harvey Research Institute, St. Bartholomew’s Hospital, Queen Mary University, London EC1A 7BE United Kingdom
  • Department of Endocrinology (R.A.), University of Antwerp, B-2610 Antwerp, Belgium
  • Third Department of Internal Medicine (V.H.), Charles University, 121 08 Prague, Czech Republic
  • Department of Endocrinology, Metabolism, and Diabetes (C.H.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden
  • Pfizer Endocrine Care (H.A.W.), Tadworth KT20 7NS, United Kingdom
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2010-06-01
Volume
95
Issue
6
Pages
2646-2654
ISSN
  • 0021-972X
  • 1945-7197
DOI
10.1210/jc.2009-2013
Cited by
32
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discontinuation of Growth Hormone (GH) Treatment during the Transition Phase Is an Important Factor Determining the Phenotype of Young Adults with Nonidiopathic Childhood-Onset GH Deficiency. https://app.cochat.ai/papers/10.1210/jc.2009-2013
The paper
Kołtowska-Häggström, M., Geffner, M. E., Jönsson, P., Monson, J. P., Abs, R., Hána, V., Höybye, C., & Wollmann, H. A. (2010). Discontinuation of Growth Hormone (GH) Treatment during the Transition Phase Is an Important Factor Determining the Phenotype of Young Adults with Nonidiopathic Childhood-Onset GH Deficiency. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-2013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.